All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
31 - 40 of 102 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Poster
Target Engagement and Saturating Effects demonstrated with quantitative 89Zr-PET imaging for the Therapeutic Anti-SIRPα Antibody BI 765063
Author(s): Pouw et al.
Beamion™ LUNG-2: a Phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations
Author(s): Johnson et al.
A Phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations: Beamion™ LUNG-2
Author(s): Wu et al.
Updated data from Beamion™ LUNG-1, a Phase Ia/b trial of the HER2-specific tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with HER2 mutation-positive NSCLC
Author(s): Wu et al.
DAREON®-7: a Phase I, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Capdevila et al.
Ezabenlimab (BI 754091) plus modified docetaxel, cisplatin, and 5-fluorouracil followed by chemoradiotherapy in patients with Stage III squamous cell carcinoma of the anus: early efficacy endpoint results from the Phase II INTERACT-ION study
Author(s): Kim et al.
First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Author(s): Champiat et al.
Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer and HER2 Mutations
Author(s): Baik et al.
A Phase Ib, open-label, dose escalation trial of the delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive glioma
Author(s): van den Bent et al.
Neoadjuvant ezabenlimab or pembrolizumab in combination with an anti-SIRPα antibody in resectable colorectal cancer
Author(s): Lucas et al.